Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by Swiss National Bank

Swiss National Bank boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 8.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,100 shares of the company’s stock after purchasing an additional 2,900 shares during the quarter. Swiss National Bank’s holdings in Krystal Biotech were worth $7,117,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its stake in shares of Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares during the last quarter. Jamison Private Wealth Management Inc. acquired a new stake in shares of Krystal Biotech during the second quarter valued at $28,000. Key Financial Inc acquired a new stake in shares of Krystal Biotech during the second quarter valued at $28,000. Blue Trust Inc. boosted its stake in Krystal Biotech by 2,328.6% in the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after buying an additional 163 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in Krystal Biotech in the 3rd quarter worth about $53,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

KRYS opened at $194.56 on Tuesday. The company has a market cap of $5.60 billion, a PE ratio of 109.92 and a beta of 0.82. The stock has a 50-day moving average of $179.55 and a 200-day moving average of $182.80. Krystal Biotech, Inc. has a 52-week low of $99.00 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm’s revenue was up 879.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.67) EPS. On average, research analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. This represents a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 14.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

KRYS has been the topic of a number of research reports. Stifel Nicolaus raised their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright reiterated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday, November 5th. Chardan Capital boosted their price objective on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $202.29.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).